CDX
SU-DHL-4
Tumor indication
Lymphoma
Tumor subtype
DLBCL (GCB)
Description
SU-DHL-4 (Lymphoma CDX Model)
The SU-DHL-4 line was derived from a diffuse large B-cell lymphoma (DLBCL). It represents one of the most common non-Hodgkin’s lymphoma subtypes. SU-DHL-4 has been widely applied in hematology drug discovery. Its reproducibility makes it valuable for lymphoma translational research.
Key Features:
- Derived from diffuse large B-cell lymphoma.
- Represents aggressive B-cell lymphoma.
- Suspension growth in culture.
- Tumorigenic in xenografts.
Applications:
SU-DHL-4 supports development of novel therapies for DLBCL. Researchers use it to study B-cell signaling pathways and therapeutic resistance. It is applied in biomarker discovery and targeted therapy testing. Its reproducibility ensures reliability in preclinical pipelines.
Details
- Tumor indication
- Lymphoma
- Tumor subtype
- DLBCL (GCB)
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.